Microfluidic Kidney Organoid Culture for PKD Cyst Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current models for studying autosomal dominant polycystic kidney disease (PKD) are limited by a lack of understanding of its mechanisms and do not accurately replicate the human disease, necessitating an improved in vitro model that mimics the kidney microenvironment.
Innovation Solution
A method and system for culturing genetically modified human kidney organoids in a flow device with controlled fluid properties to simulate physiological conditions, allowing for the formation and study of PKD cysts, using genetic modifications in PKD1 and PKD2 genes and fluid flow to replicate cyst formation and expansion mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If murine models are used to study PKD, then animal experimentation is simplified, but the models do not fully phenocopy or genocopy the human disease
Solution Approach 1:
The patent uses human pluripotent stem cells to create organoids that are human-specific models, copying human kidney tissue architecture and physiology in vitro. This approach creates a human disease model that accurately phenocopies human PKD without requiring animal experimentation, thereby maintaining ease of model creation while significantly improving disease phenocopy accuracy.
Solution Approach 2:
The patent introduces human pluripotent stem cells as an intermediary system that bridges the gap between simple animal models and complex human in vivo systems. These stem cells can be differentiated into kidney organoids that exhibit human-specific PKD pathology, serving as a mediator that provides both experimental simplicity and human disease relevance.
2Reliability
If in vivo studies are conducted to understand PKD mechanisms, then physiological relevance is maintained, but the complexity of deciphering mechanisms increases
Solution Approach 1:
The patent extracts the essential kidney microenvironment and PKD pathogenesis mechanisms from the complex in vivo system and recreates them in a controlled in vitro organoid system. By taking out the key physiological features and disease mechanisms while removing the complexity of whole-organism physiology, the patent achieves physiological relevance with reduced system complexity.
Solution Approach 2:
The patent segments the kidney function and PKD pathology into discrete organoid structures that can be individually studied. By dividing the complex kidney system into manageable organoid units with specific functional characteristics, the patent maintains physiological relevance while enabling focused mechanistic studies without the overwhelming complexity of in vivo systems.
3Ease of operation
If static culture conditions are used for kidney organoids, then culture simplicity is maintained, but the kidney microenvironment is not adequately replicated
Solution Approach 1:
The patent implements dynamic flow conditions in the culture system, where media is continuously perfused through the organoid culture at controlled flow rates. This dynamic approach replicates the physiological flow conditions in the kidney microenvironment, improving microenvironment replication while maintaining operational simplicity through automated flow control systems.
Solution Approach 2:
The patent uses hydraulic flow systems to deliver culture media through the organoid cultures, replicating the fluid dynamics of the kidney microenvironment. By applying controlled fluid flow rather than static culture conditions, the patent adequately replicates the mechanical and chemical aspects of the kidney microenvironment while maintaining ease of operation through standard bioreactor technology.
Data Source
AI summary
Microfluidic systems, kits, and methods for characterization of polycystic kidney disease (PKD) are described. In an embodiment, the microfluidic system includes a flow device comprising an inlet, an outlet, and a channel comprising a functionalized site configured for cell culture. In an embodiment, a genetically modified (GM) human kidney organoid is cultured at the functionalized site, optionally in the presence of a fluidic flow, to produce PKD cysts for use as a model system for characterization of mechanisms of PKD onset, progression, diagnosis, and response to treatment.